UNSPSC 85251811: Diagnosis of malignant neoplasm on the overlapping lesion of bone and articular cartilage

This classification denotes the group of activities that yields a diagnosis of Malignant neoplasm on the Overlapping lesion of bone and articular cartilage. Malignant neoplasm on the Overlapping lesion of bone and articular cartilage is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code C41. 8

UNSPSC 85251811 Diagnosis of malignant neoplasm on the overlapping lesion of bone and articular cartilage is a Commodity code that shows little relevant recent state and local procurement activity. The three most recent opportunities tagged under this code—a diagnostic imaging PACS system implementation at San Mateo Medical Center, special education contracted services at Birdville Independent School District in Texas, and a temporary health professional staffing pool established by Santa Clara County Health System—do not align with the code's nominal scope of oncologic bone and cartilage pathology diagnosis. The San Mateo Medical Center solicitation addresses enterprise imaging infrastructure and data migration; the Birdville ISD opportunity covers educational support services including audiology, speech therapy, and behavioral analysis; and the Santa Clara Health System qualification vehicle establishes a vendor pool for ancillary clinical staffing across multiple specialties. None of these procurements target diagnostic pathology services, malignancy screening, or bone and joint biopsy interpretation.

State and local procurement bodies appear to have applied this code inconsistently or as a catch-all category that does not reflect actual buying patterns under it. The geographic spread of tagged opportunities spans California (San Mateo and Santa Clara counties) and Texas (Tarrant County), but the mismatch between the code's clinical focus and the work being solicited undermines confidence in using this code as a signal of relevant demand. Buyers pursuing state and local contracts in oncologic pathology, diagnostic imaging, or related clinical services should verify the actual scope of opportunities through direct RFP, RFQ, and IFB review rather than rely on this code's tagging to surface related work.